News

Skyphos to Showcase Additive Lithography at the Microfluidics Consortium Open Day in Boston

Skyphos Technologies, a Virginia Tech Corporate Research Center company advancing micro-scale and additive lithography manufacturing, will participate in the Microfluidics Consortium Open Day Meeting in Boston, where the company has been invited to present in the Physical Microfluidics Hotseat and deliver a tabletop demonstration.

The Microfluidics Consortium convenes worldwide leaders, from research and industry, bringing together stakeholders from materials, device development, instrumentation, and applications to accelerate adoption of microfluidics-enabled products and services. The Boston meeting is part of the consortium’s international event series and is organized around expert talks, startup hot-seat pitches, live demonstrations, and face-to-face networking.

At the event, Skyphos will highlight its advanced micro-fabrication platform and vertically integrated approach, aimed at enabling scalable, high-precision production of microdevice architectures outside of the clean room at scale. Skyphos specializes in components and process development relevant to lab-on-a-chip systems and related applications.

Participation in the Physical Microfluidics Hot-Seat places Skyphos alongside emerging companies and thought leaders presenting new approaches in the fields of diagnostics, therapeutics, organ-on-chip, synthetic biology, and next-generation microfluidic systems. The consortium’s broader mission is to connect participants from across Europe, the United States, and Asia to help move promising microfluidics technologies from concept toward commercial use.

“Skyphos is building manufacturing infrastructure for the next generation of microfluidic devices,” said Elliot McAllister- Founder. “This invitation to Boston reflects a growing recognition that scalable microfabrication remains a key bottleneck to the field. Skyphos and others are showing that new manufacturing models can translate and grow strong techniques and applications. Getting cures from lab to fab.”

Located within the Virginia Tech Corporate Research Center community, Skyphos represents the kind of deep-tech company the CRC was built to support: a venture combining advanced engineering, research-driven innovation, and commercial ambition. The company’s participation in Boston underscores the reach of Virginia-based innovation in emerging sectors where manufacturing and life sciences intersect.

 

Recent News

06/02/2026

TearSolutions Receives FDA Orphan Drug and Fast Track Designations for Lacripep® in Neurotrophic Keratitis and Initiates Phase 2 Clinical Trial with First Patients Dosed

TearSolutions, Inc. (“TearSolutions”), a clinical-stage biotechnology company developing novel ophthalmic therapeutics, today announced receiving Food and Drug Administration (FDA) Orphan Drug (ODD) and Fast Track Designations for Lacripep in Neurotrophic Keratitis (NK) and initiating a Phase 2 clinical trial with first patients dosed. The FDA’s ODD provides incentives, including tax credits for clinical testing and

06/02/2026

Contraline Announces $92.5 Million Series B Financing to Advance NES/T Male Contraceptive into Late-Stage Development

Contraline, Inc., a clinical-stage biopharmaceutical company developing novel male contraceptives, today announced the closing of a $92.5 million Series B financing co-led by BVF Partners L.P. and RA Capital Management, with participation from GV (Google Ventures), Lumira Ventures, Invus, and other new and existing investors. In conjunction with the closing of the Series B financing,

06/02/2026

GEN Names BioHealth Capital Region a Top 3 U.S. Biopharma Cluster for Fourth Year in a Row

The BioHealth Capital Region, spanning Maryland, Virginia, and Washington, D.C., has once again been named one of the nation’s Top 3 biopharma clusters by Genetic Engineering & Biotechnology News (GEN), marking the region’s fourth consecutive year in the Top 3. GEN’s 2026 “Top 10 U.S. Biopharma Clusters” ranking was authored by Alex Philippidis, Senior Business